US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Oncotelic Therapeutcs Inc
(OP:
OTLC
)
0.0208
-0.0002 (-0.95%)
Delayed Quote
Updated: 3:16 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oncotelic Therapeutcs Inc
< Previous
1
2
3
4
5
6
7
Next >
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens BIO REBOOT Registration, Announces PDAOAI Presentations at Drug Discovery 2026
October 05, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
OTCQB Virtual Investor Conference Presentations Now Available for On-Demand Viewing
August 07, 2026
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present at OTCQB Virtual Investor Conference
August 03, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th
August 03, 2026
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
OTCQB Virtual Investor Conference Agenda Announced for August 5 & 6
July 30, 2026
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Preclinical Data Supporting IV Cancer Therapy
July 22, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Brings AI and Robotics Together in New Platform
July 15, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Oncotelic Therapeutics Inc. (OTLC) Targets Biotech’s Manufacturing Bottleneck with AI-Powered GMP Platform
July 09, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports Positive Safety Review for Phase 1b Sapu003 Trial
July 07, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Peer-Reviewed Validation of Deciparticle(TM) Platform
June 29, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
NetworkNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Eyes Opportunity Through AI and Pharmaceutical Automation
June 24, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation
June 23, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Launches AI-Powered GMP Manufacturing Services Platform at BIO 2026
June 18, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
AINewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Advances Robotics Deployment at SAPU Bio Sterile Manufacturing Facility
June 17, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI-Powered GMP Manufacturing Platform
June 17, 2026
Via
Investor Brand Network
Topics
Intellectual Property
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Showcase AI Drug Discovery Platform at Qdrant Vector Space Day 2026
June 08, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Oncotelic Therapeutics Inc. (OTLC) Combines Nanomedicine, AI, and Robotics to Advance Precision Oncology and Rare Disease Innovation
June 05, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on Advanced Cancer Drug Delivery
June 05, 2026
Via
Investor Brand Network
Topics
Intellectual Property
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies
June 05, 2026
From
NetworkNewsWire
Via
GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Drug-Delivery Market Growth
June 04, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
June 04, 2026
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Sapu003 Phase 1b Program, Appoints Global CRO for International Study Execution
June 03, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
June 03, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
From
BioMedWire
Via
GlobeNewswire
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Cancer Drug Delivery Technologies
June 02, 2026
Via
Investor Brand Network
Topics
Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Cancer Drug Delivery Technologies
June 02, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
June 02, 2026
From
Oncotelic Therapeutics, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies
June 01, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
June 01, 2026
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
Next >
